New Study Shows Nutrient Combination Reduces the Increase in Blood Glucose Levels After Eating Carbohydrates in Moderately Obese People with Type 2 Diabetes

Results from Diachrome® Clinical Trial Presented at
North American Association for the Study of Obesity (NAASO) Conference

LAS VEGAS, NV, November 16, 2004 – (Nutrition 21, Inc. NASDAQ: NXXI) – Results from a new randomized double-blind, placebo controlled study suggest that the combination of chromium picolinate and biotin, marketed as Diachrome®, reduces the glycemic response in moderately obese individuals with type 2 diabetes when given an oral carbohydrate solution. The results of the study, which evaluated 36 subjects over 30 days, were presented today at the Annual Scientific Meeting of North American Association for the Study of Obesity (NAASO) in partnership with the American Diabetes Association at Las Vegas, NV and the abstract is published in the October 2004 issue of Obesity Research.
This trial found significant improvements in blood glucose control in people who added Diachrome to their diabetes treatment regimen, compared to the placebo group. Blood glucose levels were measured at 0, 30, 60, 90 and 120 minutes following consumption of 75 grams of an oral carbohydrate solution. In the Diachrome group, a significant decrease (p<0.03) was seen in the total increase of blood glucose levels over 2 hours (area under the curve – AUC) after consumption.

“The results of this study suggest improved carbohydrate metabolism and better glucose control for people who are obese with type 2 diabetes and are concerned about managing post prandial glucose levels after a high carbohydrate meal,” according to James Komorowski, MS, Vice President, technical services and scientific affairs for Nutrition 21, which commissioned the study. “It was very encouraging to see these positive benefits in only 30 days after taking Diachrome,” added Mr. Komorowski.

According to NAASO, over seventeen million Americans have type 2 diabetes, and 90 percent of this population is considered overweight. Type 2 diabetes is linked to obesity and physical inactivity, and over a long period of time, high blood sugar levels and diabetes can cause heart disease, stroke, blindness, kidney failure, leg and foot amputations, and pregnancy complications.

“As the research builds, Diachrome is increasingly being considered by healthcare professionals as an adjunct therapy for type 2 diabetes individuals whose blood sugar levels are not tightly controlled through medications,” said Gail Montgomery, President and CEO of Nutrition 21. “These outcomes indicate that Diachrome may have dramatic short term health benefits that could lead to improved and more affordable patient care.”
Current research also suggests Diachrome may improve cardiovascular risk factors, including decreased triglyceride and lipid level ratios such as total cholesterol/HDL cholesterol associated in people with diabetes and cardiovascular disease.

About Nutrition 21, Inc.
Nutrition 21 is a biosciences company dedicated to the research, development and commercialization of innovative chromium-based nutrition products for improved health maintenance, and for the prevention and treatment of metabolic diseases such as diabetes, insulin resistance, obesity, depression and cardiovascular disease. Nutrition 21 holds 34 patents for nutrition products, 25 of which are for chromium compounds and their uses. More information is available at or or call 1-866-DIACHROME.


Stacey Antine, MS, RD,

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.